Enjoy complimentary customisation on priority with our Enterprise License!
The liposomal products market size is forecast to increase by USD 3.99 billion at a CAGR of 10.87% between 2023 and 2028. The growth of the market depends on several factors, including the rising incidence of fungal disorders, the growing prevalence of cancer cases, and many side effects associated with cancer treatment. However, late diagnosis and poor survival rates of patients with cancer are major challenges in the liposome drug delivery market. Companies are increasingly focussing on the market trends such as strategic alliances, and rising adoption of quality by design (QbD) over traditional processes to overcome the challenges.
It also includes an in-depth analysis of market trends and analysis, market growth analysis and challenges. Furthermore, the report includes historic market data from 2018 - 2022.
To learn more about this report, View Report Sample
The market: Liposomes, consisting of phospholipid bilayers, have revolutionized drug delivery through nanosizing techniques. Various drug loading methods ensure efficient encapsulation within these vesicles, with critical quality attributes ensuring efficacy. Liposomal formulations range from unilamellar to multivesicular vesicles, classified by their structure—oligolamellar, multilamellar, small, large, and giant unilamellar. Components like glycerolphospholipids, sphingomyelin, and cholesterol influence stability and permeability. Surface modifications with methoxyPEG enhance circulation time. Liposomal carriers deliver diverse drugs via mechanisms like diffusion or cell fusion, with amphotericin being a notable example. Data Bridge and expert analysis inform pipeline analysis and regulatory frameworks governing liposomal therapeutics, shaping the market for these spherical-shaped vesicles. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing prevalence of cancer cases is a major market driver. Cancer is a common chronic disease and a growing health issue globally, caused by genetic mutations, environmental factors like smoking and pollution, and changing diets. This has led to a rise in cases and deaths, making it the second leading cause of death worldwide.
Breast, prostate, and lung cancers are prevalent in North America and Europe, with breast cancer now the most commonly diagnosed type globally. Accurate registration of patients is crucial for medical research and healthcare planning. As cancer incidence and prevalence increase, the demand is expected to grow, driving market growth.
The rising adoption of quality by design (QbD) over traditional processes is the primary trend in the market. The adoption of rational-based approaches such as QbD over empirical and simulation-based approaches has been contributing to streamlined processes. QbD is based on a fact-based rational approach and helps manufacturing companies for better robust decision-making as compared to traditional approaches based on trial and error. Moreover, the global regulatory authorities are converging toward process and regulatory harmonization for the manufacturing of liposomal formulation.
The QbD approach is expected to witness increased popularity and rising adoption. The adoption of QbD in manufacturing processes is likely to contribute towards better quality, gradation, and consistency of excipient supply, which, in turn, will lead to better final products or drugs. Thus the rising adoption of QbD will further enhance the growth of the liposome drug delivery market during the forecast period.
Late diagnosis and poor survival rate of patients with cancer is the major challenge impeding the liposome drug delivery market growth. Almost half of cancer patients are diagnosed at late stages as per the NHS, in the UK. In the late stages of cancer, it becomes difficult to control tumor growth. The late diagnosis at the primary care level occurs because of the failure to recognize and investigate the symptoms of cancer. This is because most patients with cancer show non-specific symptoms, which are difficult for primary healthcare physicians to analyze and identify. Similarly, at the secondary care level, the lack of adequate treatment contributes to the poor diagnosis and survival of patients with cancer.
During the late stages, the treatment using drug therapies becomes difficult, and surgery is often performed in such cases. Hence, the late diagnosis and the poor survival rate associated with cancer limit the use of these as well as increase the mortality rates associated with cancer. Hence, such factors may hamper the growth of the liposomal drugs market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Galen-pharma - The company offers liposomal product solutions such as DaunoXome. The company offers products under the categories of pain management, dermatology, and gastroenterology.
The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The liposome drug delivery market share growth of the cancer segment will be significant during the forecast period. Liposomal products are increasingly used in cancer therapy. Advancements in liposomal vesicle development have achieved both targeted drug delivery and controlled drug release. This property of liposomes is necessarily helpful for cancer treatment. Therefore rising cases of cancer diagnosis will fuel the market growth during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The cancer segment was valued at USD 1.96 billion in 2018. Liposomal drug delivery systems are used as targeted therapy for cancer treatment in surgical resection, chemotherapy, and radiation therapy. Therefore, the rise in the cancer incidence rate globally is expected to enhance the demand during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
Asia is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
North America holds the largest share of the market owing to the huge investments made in the oncology sector in the US. The US dominates the regional market and acts as the major revenue generator, followed by Canada. Huge investments in the pharmaceutical industry, specifically the oncology sector, and the presence of pharmaceutical giants in the region are some of the major factors backing the dominance of the US.
Cancer is one of the most common chronic diseases in the US. Also, in every 100,000 population, 436 new cancer cases were reported, and about 156 died of cancer in the country. Thus, with the growing incidences of cancer, Companies will invest in extensive research to develop effective drugs for the treatment of several cancers. As cancer drugs are associated with several side effects, the demand is expected to increase in the region during the forecast period.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Hydrolyzed Collagen Market: Hydrolyzed Collagen Market by Application and Geography - Forecast and Analysis
Doxorubicin Market: Doxorubicin Market by Formulation, End-user, and Geography - Forecast and Analysis
Oleochemicals Market: Oleochemicals Market by Product, Application, and Geography - Forecast and Analysis
The market for liposomal products is driven by advancements in nanosizing techniques ensuring precise delivery and critical quality attributions for efficacy. From unilamellar to multilamellar vesicles, diverse structures like oligolamellar and multivesicular liposomes accommodate varied drugs including Doxil, Arikaye, and Vyxeos. Regulatory bodies like the FDA and EMA provide guidelines, with counterparts like the Chinese NMPA shaping regulatory frameworks. Nanomedicines adhere to stringent nonclinical pharmacokinetics guidelines, exemplified by ThermoDox and Lipusu. Imaging modalities like SPECT imaging utilize paramagnetic liposomes, while therapeutic interventions leverage PEGylated liposomal Doxorubicin and Amphotericin B liposome. With global presence and diverse applications spanning diagnostics to therapeutics, liposomal products navigate trade routes and domestic tariffs to generate revenue in the dynamic pharmaceutical landscape. The regulatory framework ensures compliance with standards for the Production capacities and distribution of Small unilamellar, Large unilamellar, spherical-shaped vesicle, including unilamellar vesicles and oligolamellar vesicles, created through nanosizing technique with glycerolphospholipid.
Market Scope |
|
Report Coverage |
Details |
Page number |
173 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.87% |
Market growth 2024-2028 |
USD 3.99 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
9.53 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Asia at 35% |
Key countries |
US, Germany, China, France, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Acthera Therapeutics AG, Bausch Lomb Corp., Baxter International Inc., Galen Ltd., GENFIT SA, Gilead Sciences Inc., Innocan Pharma Corp. Ltd., Johnson and Johnson Services Inc., Leadiant Biosciences Inc., Lipella Pharmaceuticals Inc., Liposoma B.V., Merrimack Pharmaceuticals Inc., Nanovex Biotechnologies SL, Pacira BioSciences Inc., Spectrum Pharmaceuticals Inc., Taiwan Liposome Co. Ltd., Takeda Pharmaceutical Co. Ltd., The Lubrizol Corp., Vascular Biosciences, and Viatris Inc. |
Market dynamics |
Parent market analysis, Market Forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.